Selenium

Selenium Therapeutics is a biotechnology company focused on developing a new class of cancer therapies that exploit the vulnerabilities of selenium-dependent enzymes. The company's primary focus is on targeting Glutathione peroxidase 4 (GPX4), a master regulator of ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation. By inhibiting GPX4, Selenium Therapeutics aims to induce cell death in therapy-resistant cancer cells that have entered a high-mesenchymal, drug-tolerant state. The company's approach leverages deep expertise in chemical biology to create selective small molecule inhibitors for difficult-to-treat solid tumors.